US 12,319,967 B2
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
Daniel G. Gioeli, Charlottesville, VA (US)
Assigned to University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on Nov. 11, 2020, as Appl. No. 17/095,511.
Application 17/095,511 is a continuation in part of application No. 16/999,959, filed on Aug. 21, 2020, granted, now 11,788,091.
Claims priority of provisional application 62/889,705, filed on Aug. 21, 2019.
Prior Publication US 2021/0071268 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 15 Claims
 
1. A method of determining the presence of and/or expression level of hormone upregulated long noncoding RNA within LCK gene (HULLK) in a subject, the method comprising:
providing a sample from a subject, wherein the sample comprises a biofluid or bodily fluid;
contacting the sample, with or without prior concentration of the sample, with a reagent, wherein the reagent comprises one or more primers selected from the group consisting of SEQ ID NOs. 2-24; and
determining the presence of and/or expression level of HULLK in the sample based on the contacting, wherein determining the presence of and/or expression level of HULLK in the sample comprises using polymerase chain reaction (PCR) to amplify one or more regions of a lymphocyte-specific protein tyrosine kinase (LCK) gene using the reagent, wherein the one or more regions of the LCK gene comprise exons 1-5 and exon 6-3′UTR.